Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 6, 2000
Last updated: August 25, 2011
Last verified: August 2011

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for treating anaplastic large cell lymphoma.

PURPOSE: This randomized phase III trial is studying several different regimens of combination chemotherapy to compare how well they work in treating children with anaplastic large cell lymphoma.

Condition Intervention Phase
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: leucovorin calcium
Drug: methotrexate
Drug: therapeutic hydrocortisone
Drug: vinblastine sulfate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Event-free survival [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival [ Designated as safety issue: No ]
  • Complete remission achieved after treatment course B3 and lasting ≥ 4 weeks [ Designated as safety issue: No ]
  • Short- and long-term toxicity [ Designated as safety issue: Yes ]
  • Nonlymphoma related death and early deaths (excluding deaths occurring after second-line treatment for failure or relapse) [ Designated as safety issue: No ]
  • CNS relapses [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: December 1999
  Show Detailed Description


Ages Eligible for Study:   up to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically proven standard-risk (SR) or high-risk (HR) anaplastic large cell lymphoma

    • SR disease defined by no involvement of the skin, mediastinum, liver, spleen, or lung
    • HR disease defined by any of the following:

      • Biopsy proven skin lesions (except skin lesions overlying an involved node or isolated skin disease)
      • Mediastinal involvement by x-ray or CT scan
      • Involvement of the liver (enlarged by at least 5 cm and/or nodular), spleen (enlarged and/or nodular), or lung (biopsy not needed for obvious lesions)
  • Histologic or cytologic slides must be available for national pathology review for all patients not meeting the classical criteria for diagnosis (typical histopathology, immunohistochemistry: CD30 positive, endomysial antibody positive, nucleophosmin negative, anaplastic lymphoma kinase (ALK) positive (if available), null or T-immunophenotype) unless proven t(2;5)
  • Must enroll within 1 week prior to beginning study regimen A
  • No CNS involvement (CSF or cerebral tumor)
  • First randomization (SR or HR disease):

    • Must have begun prephase therapy
    • No isolated primary skin disease
    • No low-risk disease defined as completely resected stage I disease
  • Second randomization (HR disease only):

    • Must have completed first randomization therapy without disease progression



  • Under 22

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • See Disease Characteristics


  • See Disease Characteristics


  • Not specified


  • See Disease Characteristics


  • No congenital immunodeficiency
  • No AIDS


  • No prior malignancy


Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • Prior corticosteroids for anaplastic large cell lymphoma allowed if given for no more than 8 days


  • Not specified


  • No prior organ transplantation


  • No other prior therapy for anaplastic large cell lymphoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00006455

St. Anna Children's Hospital
Vienna, Austria, A-1090
U.Z. Gasthuisberg
Leuven, Belgium, B-3000
Institut Gustave Roussy
Villejuif, France, F-94805
Giessen, Germany, D-35385
Azienda Ospedaliera di Padova
Padova, Italy, 35128
Dutch Childhood Leukemia Study Group
Den Haag, Netherlands, 2504 AM
Hospital Clinico Universitario de Valencia
Valencia, Spain, 46010
Karolinska University Hospital - Huddinge
Stockholm, Sweden, S-171 76
University Children's Hospital
Zurich, Switzerland, CH-8032
United Kingdom
Addenbrooke's Hospital
Cambridge, England, United Kingdom, CB2 2QQ
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Study Chair: Laurence Brugieres, MD Gustave Roussy, Cancer Campus, Grand Paris
  More Information

Additional Information:
Publications: Identifier: NCT00006455     History of Changes
Other Study ID Numbers: CDR0000068133, FRE-IGR-ALCL99, EU-20031, NHL2000/06
Study First Received: November 6, 2000
Last Updated: August 25, 2011
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage I childhood anaplastic large cell lymphoma
stage II childhood anaplastic large cell lymphoma
stage III childhood anaplastic large cell lymphoma
stage IV childhood anaplastic large cell lymphoma
recurrent childhood anaplastic large cell lymphoma

Additional relevant MeSH terms:
Lymphoma, Large-Cell, Anaplastic
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Cortisol succinate
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Anti-Inflammatory Agents
Dermatologic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on March 03, 2015